PROCEPT BioRobotics Corp (PRCT)
64.31
+2.57
(+4.16%)
USD |
NASDAQ |
May 03, 16:00
64.28
-0.03
(-0.05%)
After-Hours: 20:00
PROCEPT BioRobotics Cash from Financing (TTM): 170.00M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 170.00M |
December 31, 2023 | 167.80M |
September 30, 2023 | 163.61M |
June 30, 2023 | 2.269M |
March 31, 2023 | 2.701M |
Date | Value |
---|---|
December 31, 2022 | 3.612M |
September 30, 2022 | 5.574M |
June 30, 2022 | 178.92M |
March 31, 2022 | 262.18M |
December 31, 2021 | 262.12M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.269M
Minimum
Jun 2023
262.18M
Maximum
Mar 2022
121.88M
Average
165.70M
Median
Cash from Financing (TTM) Benchmarks
Globus Medical Inc | -231.82M |
Glaukos Corp | 27.06M |
Integra Lifesciences Holdings Corp | -229.92M |
Intuitive Surgical Inc | 46.90M |
Masimo Corp | -57.10M |